Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering
Morgan Stanley,
A registration statement on Form S-1 relating to the shares being sold in this offering was filed with and declared effective by the
The offering is being made only by means of a prospectus. When available, a copy of the prospectus may be obtained from
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding an offering of Outset’s common stock. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. These risks and uncertainties, many of which are beyond Outset’s control, include, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering, and other risks described in the section entitled “Risk Factors” in the preliminary prospectus related to this offering filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210409005225/en/
Investor Contact
investors@outsetmedical.com
Source: